Brief: Astrazeneca-Ultomiris Demonstrated 43.4% Reduction In Proteinuria Versus Placebo In Adults With Immunoglobulin A Nephropathy At 34 Weeks In Phase III Trial
06/06/2026 10:29
BRIEF-Astrazeneca-Ultomiris Demonstrated 43.4% Reduction In Proteinuria Versus Placebo In Adults With Immunoglobulin A Nephropathy At 34 Weeks In Phase III Trial June 6 (Reuters) - AstraZeneca PLC AZN.L:
ASTRAZENECA-ULTOMIRIS DEMONSTRATED 43.4% REDUCTION IN PROTEINURIA VERSUS PLACEBO IN ADULTS WITH IMMUNOGLOBULIN A NEPHROPATHY AT 34 WEEKS IN PHASE III TRIAL
Source text: [ID:]
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsUK Market Exodus: Companies that moved away from London listing in recent years
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal (updated)
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal